This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Open AccessArticle
Lacticaseibacillus casei IB1 Alleviates DSS-Induced Inflammatory Bowel Disease by Regulating the Microbiota and Restoring the Intestinal Epithelial Barrier
by
Jianlong Lao
Jianlong Lao 1,2,
Shuping Yan
Shuping Yan 1,
Yanhong Yong
Yanhong Yong 1,
Yin Li
Yin Li 1,
Zhaohai Wen
Zhaohai Wen 1,
Xiaoyong Zhang
Xiaoyong Zhang 1,
Xianghong Ju
Xianghong Ju 1,2,* and
Youquan Li
Youquan Li 1,2,*
1
College of Coastal Agricultural Sciences, Guangdong Ocean University, Zhanjiang 524088, China
2
Marine Medical Research and Development Centre, Shenzheng Institute of Guangdong Ocean University, Shenzheng 518120, China
*
Authors to whom correspondence should be addressed.
Microorganisms 2024, 12(7), 1379; https://doi.org/10.3390/microorganisms12071379 (registering DOI)
Submission received: 26 April 2024
/
Revised: 18 June 2024
/
Accepted: 4 July 2024
/
Published: 6 July 2024
Abstract
Inflammatory bowel disease (IBD) is becoming an increasingly serious health problem in humans and animals. Probiotics can inhibit the development of IBD. Due to the specificity of the strains, the function and mechanism of action of different strains are still unclear. Here, a DSS-induced colitis mouse model was utilized to investigate the ability and mechanism by which Lacticaseibacillus casei IB1 alleviates colitis. Treatment with L. casei IB1 improved DSS-induced colitis in mice, as indicated by increased body weight, colon length, and goblet cell numbers and decreased disease activity index (DAI), proinflammatory factor (TNF-α, IL-1β, and IL-6) levels, and histopathological scores after intake of IB1. IB1 supplementation also improved the expression of tight junction proteins and inhibited the activation of the MAPK and NF-κB signaling pathways to alleviate intestinal inflammation. In addition, IB1 rebalanced the intestinal microbial composition of colitis mice by increasing the abundance of Faecalibaculum and Alistipes and decreasing the abundance of Bacteroides and Escherichia_Shigella. In summary, L. casei IB1 showed great potential for relieving colitis by regulating the microbiota and restoring the epithelial barrier. It can be used as a potential probiotic for the prevention and treatment of UC in the future.
Share and Cite
MDPI and ACS Style
Lao, J.; Yan, S.; Yong, Y.; Li, Y.; Wen, Z.; Zhang, X.; Ju, X.; Li, Y.
Lacticaseibacillus casei IB1 Alleviates DSS-Induced Inflammatory Bowel Disease by Regulating the Microbiota and Restoring the Intestinal Epithelial Barrier. Microorganisms 2024, 12, 1379.
https://doi.org/10.3390/microorganisms12071379
AMA Style
Lao J, Yan S, Yong Y, Li Y, Wen Z, Zhang X, Ju X, Li Y.
Lacticaseibacillus casei IB1 Alleviates DSS-Induced Inflammatory Bowel Disease by Regulating the Microbiota and Restoring the Intestinal Epithelial Barrier. Microorganisms. 2024; 12(7):1379.
https://doi.org/10.3390/microorganisms12071379
Chicago/Turabian Style
Lao, Jianlong, Shuping Yan, Yanhong Yong, Yin Li, Zhaohai Wen, Xiaoyong Zhang, Xianghong Ju, and Youquan Li.
2024. "Lacticaseibacillus casei IB1 Alleviates DSS-Induced Inflammatory Bowel Disease by Regulating the Microbiota and Restoring the Intestinal Epithelial Barrier" Microorganisms 12, no. 7: 1379.
https://doi.org/10.3390/microorganisms12071379
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details
here.
Article Metrics
Article metric data becomes available approximately 24 hours after publication online.